The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
We evaluated the safety and immunogencity of a novel vaccine directed against autologous TNFα in a Phase I fixed dose escalation trial. The vaccine consisted of two recombinant TNFα proteins, with specific peptides replaced by foreign immunodominant T cell epitopes from tetanus toxoid. The main objectives were to establish a safe dose and evaluate the vaccines ability to raise neutralising TNFα antibodies...
Introduction: One of the characteristics of tumor cells is the aberrant glycosylation of their surface proteins and lipids. Small and immaturely terminated O-glycans, like αGaINAc (the Tn antigen), αNeuNAc(2-6)αGaINAc (the S-Tn antigen), and βGal(1-3)αGaINAc (the T antigen), are frequently found to accumulate on the surface of adenocarcinomas. The aim of this study has been to investigate the T...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.